TRVG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
TRVG is not a good buy right now for an impatient entry. The longer-term trend is still bearish (SMA200 > SMA20 > SMA5) and price is sitting right under near-term resistance (~2.86–2.88), which makes immediate upside less attractive versus the risk of another rejection. Options positioning is call-skewed, but implied volatility is extremely elevated, suggesting speculative sentiment and expensive optionality rather than a clean, low-risk stock entry. Best stance: HOLD/AVOID new buys at this level.
Price/levels: Post-market ~2.84–2.86. Pivot 2.812 (near-term balance point). Immediate resistance at R1 2.856 and R2 2.883; support at S1 2.768 then S2 2.741. Trend: Bearish moving-average stack (SMA200 > SMA20 > SMA5) indicates the broader trend remains down. Momentum: MACD histogram is positive and expanding (0.00714), signaling short-term momentum improvement; RSI(6) ~61.5 is neutral-to-slightly-bullish but not overbought. Setup read: This looks like a short-term bounce attempt inside a bigger bearish structure, with price pressing into resistance. For an immediate buy, the reward/risk is not compelling unless it cleanly breaks and holds above ~2.88; otherwise the higher-probability move is chop/retest toward ~2.81 or lower.
and clears ~2.
Options market is heavily call-skewed (bullish sentiment).
Primary technical trend remains bearish (SMA200 > SMA20 > SMA5), increasing risk that rallies fail at resistance.
Profitability deterioration in 2025/Q3: Net income and EPS down sharply YoY, which undermines the quality of the revenue growth.
Analyst tone is mostly Neutral with recent price target cuts by Citi, Mizuho, and Susquehanna; implies limited near-term conviction on sustained upside.
Extremely elevated implied volatility suggests the market expects big swings; for stock buyers, that often coincides with unstable pricing and "priced-in" optimism.
No supportive news flow in the past week to provide a fresh catalyst right now.
Latest quarter: 2025/Q3. Revenue: 165.576M, +13.34% YoY (good top-line growth). Net income: 11.027M, -171.46% YoY (meaningfully worse profitability vs prior year). EPS: 0.03, -175% YoY (profit per share down sharply). Gross margin: 97.32%, -0.70% YoY (still very high but slightly compressed). Bottom line: Growth is present on revenue, but the quarter shows a clear profitability downdraft—this weakens the case for an aggressive buy at resistance.
Recent changes: Predominantly Neutral with multiple target cuts after Q3. Citi cut PT to $3.35 (Neutral), Mizuho cut to $3.00 (Neutral), Susquehanna cut to $3.25 (Neutral). B. Riley is the outlier with a Buy and higher PT raised to $6. Wall Street pros: Q3 results were viewed as "good/solid" by some; potential upside if marketing efficiency and growth durability improve. Wall Street cons: Repeated Neutral stances and lowered targets reflect doubts about the durability/quality of growth and overall conviction. Influential trading: Hedge funds neutral, insiders neutral; no recent Congress trading data available.
